Novo Nordisk vowed to cut costs Wednesday amid intensifying competition and a cratering stock price as it reported ...

Danish diabetes and obesity giant Novo Nordisk has announced the filing of 14 new lawsuits to safeguard patients from unsafe ...

Advanced Micro Devices ( AMD -1.39%) upped its Q3 revenue guidance to $8.4 billion to $9 billion, and Q2's $7.7 billion ...

Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with ...

H1 sales growth for Novo Nordisk’s segment that includes Ozempic and Wegovy was down from the same period in 2024.

Novo Nordisk experiences heightened competition from copycat versions of its Wegovy obesity drug, affecting its market share, ...

The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

​The real shock came with Novo's decision to slash its 2025 guidance, cutting revenue growth expectations to 8-14% and profit ...

Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

Stock futures were rising again on the eve of another tariff deadline as investors juggled strong earnings with more signs of U.S. economic weakness. Shares closed in the red Tuesday after the ISM ...